Stand with NORD and the entire Rare Disease Community to urge congress to reconsider the proposal to repeal the Orphan Drug Tax Credit.
“Repeal of this provision would squelch medical research and innovation. Repeal would remove one of the major incentives to finding cures and treatments for some of the most challenging diseases”, says Peter Saltonstall, President and CEO, National Organization for Rare Disorders (NORD).
Drug companies need more incentives to develop rare disease treatments, not less. Congress must hear from the patient community that the Orphan Drug Tax Credit is important to them.
Rare disease patient organizations wishing to sign-on to NORD’s letter to Congress on this issue should write to ODTC@rarediseases.org by COB Friday March 7.